A patent reform bill being argued in Congress has drawn a significant amount of protest from the biotech industry. But with a wide array of groups looking to influence the legislation, including the White House, the bill appears to have stalled in a Senate committee. High-tech companies, meanwhile, have been actively pushing for its passage. Report